Division of Hematology Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana.
Blood Cancer Discov. 2024 Nov 1;5(6):375-376. doi: 10.1158/2643-3230.BCD-24-0226.
In Blood Cancer Discovery, Thibaud and colleagues report the incidence of pathogenic germline variants (PGV) in patients with multiple myeloma and that these PGVs are associated with DNA repair pathway genes, including BRCA1 and BRCA2. They find an association of patients with PGVs and previous family or personal history of cancer, and that these patients are diagnosed slightly earlier than those without PGVs. Patients with PGVs had a longer progression-free survival than those without PGVs when they received high-dose melphalan and autologous stem cell transplant, providing a therapeutic rationale for diagnostic germline testing in myeloma. See related article by Thibaud et al., p. 428.
在血液癌症研究中,Thibaud 及其同事报告了多发性骨髓瘤患者中致病性种系变异(PGV)的发生率,并且这些 PGV 与 DNA 修复途径基因相关,包括 BRCA1 和 BRCA2。他们发现 PGV 患者与癌症家族史或个人病史有关,并且这些患者的诊断时间比没有 PGV 的患者稍早。在接受高剂量美法仑和自体干细胞移植时,PGV 患者的无进展生存期长于无 PGV 患者,为多发性骨髓瘤的种系检测提供了治疗依据。见 Thibaud 等人的相关文章,第 428 页。